Neoprobe starts phase 2 study of Lymphoseek in breast cancer, melanoma

By Lisa Kerner

Charlotte, N.C., July 12 - Neoprobe Corp. said it began a phase 2 multi-center clinical study evaluating the safety and efficacy of Lymphoseek, a lymphatic tissue targeting agent used to detect lymph nodes during biopsy of breast cancer and melanoma.

"We are pleased that screening and enrollment for patients has commenced," president and chief executive officer David C. Bupp said in a company news release.

"The multi-center study is designed to confirm the findings of the clinical and preclinical results that have been completed that demonstrate the benefits of Lymphoseek."

Neoprobe is a biomedical company located in Dublin, Ohio.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.